Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29575116 | 1.00 | CA1 (0.45) | CA1CA2CA9BAZ2BMAPT | |
| SCHEMBL19995817 | 0.96 | CA1 (0.45) | CA1CA2CA9BAZ2BMAPT | |
| SCHEMBL18750435 | 0.80 | CA1 (0.56) | CA1CA2CA9MAPTKDM4E | |
| SCHEMBL19995853 | 0.80 | ALDH1A1 (0.44) | BAZ2BMAPTCYP2C19CYP3A4NPC1 | |
| SCHEMBL11985027 | 0.79 | CA1 (0.43) | CA1CA2CA9MAPTKDM4E | |
| SCHEMBL8667950 | 0.79 | CA1 (0.38) | CA1CA2CA9MAPTCYP1A2 | |
| SCHEMBL8790522 | 0.79 | KDM4E (0.54) | BAZ2BMAPTKDM4ENPC1RAB9A | |
| SCHEMBL16769416 | 0.79 | CA1 (0.45) | CA1CA2CA9MAPTCYP1A2 | |
| SCHEMBL30951184 | 0.79 | PGK1 (0.48) | CA1CA2CA9BAZ2BMAPT | |
| SCHEMBL13254783 | 0.79 | HDAC1 (0.45) | CA1CA2CA9BAZ2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12338255-B2 | Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2025-06-24 | — | — | US | disclosed |
| WO-2025108255-A1 | POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2025-05-30 | — | — | WO | disclosed |
| US-12187702-B2 | Sulfonamideurea compounds | INFLAZOME LIMITED (IE) | 2025-01-07 | — | — | US | disclosed |
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| CN-118251393-A | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | 唯久生物技术(苏州)有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2023230002-A1 | NLRP3 INFLAMMASOME INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2023-11-30 | — | — | WO | disclosed |
| CN-110392678-B | Compounds and methods for IDO and TDO modulation, and indications therefor | 普莱希科公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230279026-A1 | NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2023-09-07 | — | — | US | disclosed |
| US-20230279026-A1 | NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2023-09-07 | — | — | US | disclosed |
| EP-0602851-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995030673-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-11-16 | — | — | WO | disclosed |
| EP-0673366-A1 | 5-METHANESULFONAMIDO-1-INDANONES AS AN INHIBITOR OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC. (CA) | 1995-09-27 | — | — | EP | disclosed |
| EP-0667864-A1 | TRICYCLIC COMPOUNDS WITH PHARMACEUTICAL ACTIVITY. | ZENECA LTD (GB) | 1995-08-23 | — | — | EP | disclosed |
| US-5409944-A | Enzyme inhibitors, antiinflammatory agent, antiseptic agent | MERCK FROSST CANADA, INC. (CA) | 1995-04-25 | — | — | US | disclosed |
| WO-1995009158-A1 | TRICYCLIC DERIVATIVES | ZENECA LIMITED (GB) | 1995-04-06 | — | — | WO | disclosed |
| WO-1994020480-A1 | ALKANESULFONAMIDO-1-INDANONE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE | MERCK FROSST CANADA INC. (CA) | 1994-09-15 | — | — | WO | disclosed |
| WO-1994013635-A1 | 5-METHANESULFONAMIDO-1-INDANONES AS AN INHIBITOR OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC. (CA) | 1994-06-23 | — | — | WO | disclosed |
| EP-0602851-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1994-06-22 | — | — | EP | disclosed |
| WO-1994011354-A1 | TRICYCLIC COMPOUNDS WITH PHARMACEUTICAL ACTIVITY | ZENECA LIMITED (GB) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | CA1 3947/4885CA2 2896/4885CA9 3889/4885 |
| US-12187702-B2 | Sulfonamideurea compounds | NLRP3, NOD1, NLRP1 | CA1 2764/4885CA2 1298/4885CA9 2107/4885 |
| US-20230279026-A1 | NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | CA1 3362/4885CA2 2236/4885CA9 3533/4885 |
| US-12338255-B2 | Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | CA1 3325/4885CA2 2161/4885CA9 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.